Amneal Announces Four New Generic Drugs

Lorazepam, Meclizine HCl, Promethazine HCl and Venlafaxine HCl tablets add to expanding product portfolio

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, LLC is pleased to introduce four new generic drugs – Lorazepam, Meclizine HCl, Promethazine HCl and Venlafaxine HCl - in tablet form.

Lorazepam tablets are available in 0.5 mg, 1 mg and 2 mg strengths, each offered in 100, 500 and 1000-ct. Amneal’s generic is an AB-rated, therapeutically equivalent alternative to the antianxiety drug Ativan® (a registered trademark of American Home Products Corp./Wyeth, a subsidiary of Pfizer, Inc.).

Meclizine HCl tablets are available in 12.5 mg and 25 mg strengths in 100-ct, 500-ct and 1000-ct bottles. The Amneal product is an AA-rated, therapeutically equivalent alternative to the antihistamine Antivert® (a registered trademark of Pfizer, Inc.).

Promethazine HCl tablets are available in strengths of 12.5 mg in 100-ct, 25 mg in 100 and 1000-ct and 50 mg in 100-ct. The Amneal generic is an AB-rated, therapeutically equivalent alternative to the antihistamine Phenergan® (a registered trademark of Sandoz, a division of the Novartis Group).

Venlafaxine HCl tablets are available in five strengths - 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg, each in a 90-ct bottle, one of the sizes most requested by pharmacies. Amneal’s generic is an AB-rated, therapeutically equivalent alternative to the antidepressant Effexor® (a registered trademark of Wyeth, a subsidiary of Pfizer, Inc.).

Annual U.S. sales of Lorazepam, Meclizine HCl, Promethazine HCl and Venlafaxine HCl tablets were $41.2 million, $59 million, $45.4 million and $73 million, respectively, according to April 2011 IMS Health market data.

”We are very pleased with the addition of these four new products to Amneal’s portfolio and our continued aggressive growth,” said Chirag Patel, Amneal’s president. “Going forward, the pace will accelerate as we add several new dosage forms, introduce complex and unique products and realize the results of our dramatically expanded R&D team.”

Approved by the U.S. FDA, these products are now shipping and available through wholesalers-distributors as well as directly to the trade. All Amneal generics are made in the company’s five fully cGMP-compliant, state-of-the-art manufacturing plants in the metro New York area.

Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic’s New Generation,” the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal’s aggressive growth strategy, as is the company’s strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.



CONTACT:

Amneal Pharmaceuticals, LLC
Jim Luce
Executive Vice President, Sales & Marketing
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: [email protected]
www.amneal.com

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.